Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

ClinicalTrials.gov ID: NCT06555783

Public ClinicalTrials.gov record NCT06555783. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.

Study identification

NCT ID
NCT06555783
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
93 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 26, 2024 (Actual)
Primary completion
Nov 11, 2025 (Actual)
Completion
Nov 21, 2025 (Actual)
Last update posted
Feb 27, 2026

2024 – 2025

United States locations

U.S. sites
33
U.S. states
16
U.S. cities
32
Facility City State ZIP Site status
Alkermes Investigator Site Little Rock Arkansas 72211 —
Alkermes Investigator Site Los Angeles California 90025 —
Alkermes Investigator Site Redwood City California 94063 —
Alkermes Investigator Site San Francisco California 94143 —
Alkermes Investigator Site Santa Ana California 92705 —
Alkermes Investigational Site Aurora Colorado 80045 —
Alkermes Investigator Site Colorado Springs Colorado 80918 —
Alkermes Investigator Site Brandon Florida 33511 —
Alkermes Investigator Site Miami Florida 33176 —
Alkermes Investigator Site Winter Park Florida 32789 —
Alkermes Investigator Site Atlanta Georgia 30328 —
Alkermes Investigational Site Macon Georgia 31210 —
Alkermes Investigator Site Stockbridge Georgia 30281 —
Alkermes Investigational Site Peoria Illinois 61637 —
Alkermes Investigator Site Lansing Michigan 48911 —
Alkermes Investigator Site Sterling Heights Michigan 48314 —
Alkermes Investigator Site Lincoln Nebraska 68506 —
Alkermes Investigator Site Middletown New Jersey 07748 —
Alkermes Investigator Site Denver North Carolina 28037 —
Alkermes Investigator Site Huntersville North Carolina 28078 —
Alkermes Investigator Site Canton Ohio 44718 —
Alkermes Investigator Site Cincinnati Ohio 45212 —
Alkermes Investigator Site Cincinnati Ohio 45245 —
Alkermes Investigational Site Cleveland Ohio 44195 —
Alkermes Investigator Site Abington Pennsylvania 19001 —
Alkermes Investigational Site Philadelphia Pennsylvania 19107 —
Alkermes Investigator Site Wyomissing Pennsylvania 19610 —
Alkermes Investigator Site Columbia South Carolina 29201 —
Alkermes Investigator Site Cordova Tennessee 38108 —
Alkermes Investigator Site Austin Texas 78731 —
Alkermes Investigator Site San Antonio Texas 78229 —
Alkermes Investigational Site Sugar Land Texas 77478 —
Alkermes Investigational Site Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06555783, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 27, 2026 · Synced Oct 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06555783 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →